Loading stock data…
Assembly Biosciences, Inc. (ASMB)
$26.74+2.48 (+10.22%)
Market ClosedLast close Jun 26
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Assembly Biosciences, Inc. in the Healthcare sector is trading at $26.39 with a market capitalization of $487M. Wall Street consensus targets $50.00 (4 analysts), implying a +89.4% move over the next 12 months. The stock is currently 34% below its 52-week high of $39.71, remaining 8.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +89.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.21M↓ | $42.47M↑ | $10.79M↑ | $9.63M↑ | $9.42M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$11.37M↓ | $19.80M↑ | -$10.88M↑ | -$11.09M↓ | -$9.94M |
| Net Income | -$9.08M↓ | $22.09M↑ | -$9.20M↑ | -$10.20M↓ | -$8.82M |
Peer Comparison
JNJUNHPFE
Fundamentals
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$486.91M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
307.13
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-3.21%
Volume
Today's trading volume
1.59M
Recent News
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event. Okazaki said 2024 w
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference
Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing programs in herpes simplex virus, hepatitis D and transplant-related herpes viruses. Gaggar describe
These Analysts Just Made A Huge Downgrade To Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Forecasts
Market forces rained on the parade of Assembly Biosciences, Inc. ( NASDAQ:ASMB ) shareholders today, when the analysts...
We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. Indeed, Assembly Biosciences...